Key result
In older adults undergoing PCI, abciximab use was not associated with excess in-hospital bleeding or in-hospital mortality.
Why the study?
Does abciximab increase the risk of in-hospital bleeding or mortality in older adults (≥ 75 years) undergoing PCI?
Cohort (n=5,727)
No
Does abciximab increase the risk of in-hospital bleeding or mortality in older adults (≥ 75 years) undergoing PCI?
Abciximab use during PCI in older adults (≥ 75 years) does not appear to significantly increase the risk of in-hospital bleeding or mortality, suggesting it may be safe when clinically indicated.
Answers are grounded in this paper and cite their sources.
May support abciximab in selected older PCI patients; leaves open need for randomized confirmation.
BACKGROUND: As a result of increased cost and bleeding concerns, older patients receive abciximab during percutaneous coronary intervention (PCI) less often than younger patients. OBJECTIVE: The aim of this was to evaluate the safety and efficacy of abciximab in older adults undergoing PCI. DESIGN: Retrospective, observational single centre cohort study. METHODS: The British Cardiovascular Intervention Society (BCIS) database was used to establish the impact of abciximab in people with advanced age (≥ 75 years) on in-hospital bleeding and ischaemic events and all-cause mortality in 5727 consecutive patients undergoing PCI between January 2008 and June 2014. RESULTS: Older patients represented 23% of the study population (n = 1298). Abciximab was used in 198 (15%) older patients and 970 (22%) younger patients (p < 0.001). Unadjusted bleeding and mortality rates were 1.2% and 5.6%, respectively, vs. 0.4% and 1.7% in younger patients (p = 0.001 and p < 0.001 respectively). On multivariate analysis older subjects were at higher risk of bleeding [odds ratio (OR) 2.76, 95% confidence interval (CI) 1.26-6.04, p = 0.011] and had higher in-hospital mortality (OR 2.36, 95% CI 1.48-3.74, p < 0.001). The use of abciximab in older patients was not significantly associated with excess bleeding (adjusted OR 1.86, 95% CI 0.58-5.93, p = 0.3), ischaemic outcomes (adjusted OR, 95% CI, p = 0.12) or in-hospital mortality (adjusted OR, 95% CI, p = 0.11). Older patients having primary PCI had higher risk of bleeding irrespective of abciximab use (adjusted p = 0.042). CONCLUSION: Abciximab may not be associated with excess bleeding complications in older patients compared with younger individuals and may be safe to use in older people if indicated.
No takes yet. Share an insight, caveat, or question.
Brown et al. (2015) conducted a cohort in percutaneous coronary intervention (n=5,727). abciximab vs. no abciximab was evaluated on in-hospital bleeding (OR 1.86, 95% CI 0.58-5.93, p=0.3). In older adults undergoing PCI, abciximab use was not associated with excess in-hospital bleeding or in-hospital mortality.
Synapse has enriched 10 related papers. Consider them for comparative context: